A phase I/II study of CellProtect in patients with multiple myeloma

Trial Profile

A phase I/II study of CellProtect in patients with multiple myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Natural killer cell therapy (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 New trial record
    • 15 Dec 2017 According to a CellProtect Nordic Pharmaceuticals AB, media release, the work on a clinical trial report to the Swedish Medical Products Agency is on-going and the plan is to publish the results in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top